BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 36386454)

  • 1. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
    Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
    Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
    Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
    BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
    Ma C; Li F; Gu Z; Yang Y; Qi Y
    Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
    [No Abstract]   [Full Text] [Related]  

  • 4. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
    Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
    Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
    Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
    Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
    Pan Y; Zhang Q; Zhang H; Kong F
    Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of cuproptosis-related lncRNAs to predict prognosis and immune infiltration characteristics in colorectal cancer.
    Zhu Z; Zhao Q; Li S; Weng J; Guo T; Zhu C; Xu Y
    Front Genet; 2022; 13():984743. PubMed ID: 36467996
    [No Abstract]   [Full Text] [Related]  

  • 10. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
    Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
    World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
    Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
    Front Oncol; 2022; 12():966920. PubMed ID: 36276132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients.
    Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X
    Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
    Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
    BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma.
    Wang X; Jing H; Li H
    Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
    Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
    Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
    Zhu Y; He J; Li Z; Yang W
    BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    Yang L; Yu J; Tao L; Huang H; Gao Y; Yao J; Liu Z
    Front Genet; 2022; 13():947551. PubMed ID: 35938003
    [No Abstract]   [Full Text] [Related]  

  • 20. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.